FPMI (FluoroPharma Medical) Cyclically Adjusted PB Ratio: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is FluoroPharma Medical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


FluoroPharma Medical  (OTCPK:FPMI) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


FluoroPharma Medical Cyclically Adjusted PB Ratio Related Terms


FluoroPharma Medical Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for FluoroPharma Medical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FluoroPharma Medical Cyclically Adjusted PB Ratio Chart

FluoroPharma Medical Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FluoroPharma Medical Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FPMI vs HSTC, OBMPD, GOVX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, FluoroPharma Medical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FluoroPharma Medical Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FluoroPharma Medical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where FluoroPharma Medical's Cyclically Adjusted PB Ratio falls into.



FluoroPharma Medical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

FluoroPharma Medical's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2016 is calculated as:

For example, FluoroPharma Medical's adjusted Book Value per Share data for the three months ended in Dec. 2016 was:

Adj_Book=Book Value per Share/CPI of Dec. 2016 (Change)*Current CPI (Dec. 2016)
=-0.299/241.4320*241.4320
=-0.299

Current CPI (Dec. 2016) = 241.4320.

FluoroPharma Medical Quarterly Data

Book Value per Share CPI Adj_Book
200703 0.000 205.352 0.000
200706 0.000 208.352 0.000
200709 0.000 208.490 0.000
200712 -0.001 210.036 -0.001
200803 -0.002 213.528 -0.002
200806 -0.002 218.815 -0.002
200809 -0.002 218.783 -0.002
200812 -0.003 210.228 -0.003
200903 -0.003 212.709 -0.003
200906 -0.004 215.693 -0.004
200909 -0.004 215.969 -0.004
200912 -0.004 215.949 -0.004
201003 -0.004 217.631 -0.004
201006 -0.005 217.965 -0.006
201009 -0.005 218.439 -0.006
201012 -0.174 219.179 -0.192
201103 -0.002 223.467 -0.002
201106 0.136 225.722 0.145
201109 0.137 226.889 0.146
201112 0.142 225.672 0.152
201203 0.114 229.392 0.120
201206 0.081 229.478 0.085
201209 0.044 231.407 0.046
201212 0.057 229.601 0.060
201303 0.025 232.773 0.026
201306 -0.011 233.504 -0.011
201309 0.032 234.149 0.033
201312 -0.041 233.049 -0.042
201403 -0.078 236.293 -0.080
201406 -0.132 238.343 -0.134
201409 -0.168 238.031 -0.170
201412 -0.165 234.812 -0.170
201503 -0.185 236.119 -0.189
201506 -0.234 238.638 -0.237
201509 -0.228 237.945 -0.231
201512 -0.239 236.525 -0.244
201603 -0.285 238.132 -0.289
201606 -0.303 241.018 -0.304
201609 -0.293 241.428 -0.293
201612 -0.299 241.432 -0.299

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


FluoroPharma Medical Business Description

Address 701 South Carson Street, Suite 200, Carson City, NV, USA, 89701
FluoroPharma Medical Inc is a us-based biopharmaceutical company. It specializes in developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The company focuses on the development of novel cardiovascular imaging agents which detect and assess acute and chronic forms of coronary artery disease (CAD). The company's clinical-stage molecular imaging pharmaceutical product candidates are 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). The 18-F TPP is designed for use in stress-testing for patients with proven CAD whereas 18-F FCPHA is a molecular imaging agent which is designed to assess myocardial blood flow and metabolism in patients with CAD. The company operates in a single segment being Biopharmaceutical research and development.